Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Sanofi shareholders grew nervous about negotiating a higher price for Genzyme, fearing overpayment. The CVR mechanism added uncertainty investors found…
Sanofi-aventis and Genzyme Corporation today announced that they have entered into a definitive merger agreement under which sanofi-aventis will acquire…
Manufacturing failures at Allston Landing plant forced Cerezyme and Fabrazyme supply cuts, missing CVR milestones and deflating contingent value rights held by…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Sanofi-aventis acquired Genzyme Corporation for approximately $20.1 billion ($74.00 per share in cash plus one Contingent Value Right per share), gaining a leading rare disease portfolio including Cerezyme, Fabrazyme, and the multiple sclerosis candidate Lemtrada (alemtuzumab).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Genzyme Corporation (this deal) | 2011 | $20.1B | 84 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
| Sanofi SA / Protein Sciences Corp. | 2017 | $650M | 72 |
← Browse all deals · How we score deals
More: 2011 deals · Sanofi SA deals · Metabolic deals